Black Cohosh

Black Cohosh

Black Cohosh

Common Names

  • Black snakeroot
  • rattlesnake root
  • squawroot

For Patients & Caregivers

There is some evidence that black cohosh is effective for menopausal symptoms. More research is needed.

It is not clear if black cohosh is beneficial for menopausal symptoms due to conflicting results from various studies. There is not enough evidence to support its anticancer effects in humans. Patients should use caution as liver failure has been reported from its use.

  • Menopausal symptoms
    Various studies yielded conflicting results about use of black cohosh for menopausal symptoms
  • To ease painful or heavy menstruation
    No clinical trials have evaluated this use.
  • Premenstrual syndrome (PMS)
    No clinical trials have evaluated this use
  • As a sedative
    No scientific evidence supports this use.
  • Hot flashes
    Clinical trial results are mixed.
  • Black cohosh should not be confused with blue cohosh.
  • It is still quite controversial whether or not black cohosh possesses estrogenic activity. This product should be used under the supervision of a physician.
  • You currently have, or have been treated for, an estrogen receptor-positive (ER+) cancer (It is still unclear whether black cohosh acts in the same manner as estrogen, and might therefore stimulate growth of these tumors).
  • You are taking hormonal medications such as birth control pills (If black cohosh has estrogen-like activity, it will interfere with these medicines).
  • Stomach upset
  • Liver failure
  • Hepatotoxicity has been reported following use of black cohosh.
  • Two cases of liver injury resembling autoimmune hepatitis were reported after taking black cohosh. Both patients responded to treatment with corticosteroids.
  • A case of coagulation activation, fluid retention, and transient autoimmune hepatitis has been reported associated with use of black cohosh.
  • Bradycardia (slowing of heart beat) was observed in a woman taking black cohosh.
  • Orobuccolingual dyskinesia (OBLD), involving interference with speech, tongue-biting, and eating difficulties, has been reported in a 46-year-old woman while taking a herbal supplement containing black cohosh and ginseng.

Because it is still unclear whether black cohosh has estrogenic effects, women with estrogen receptor-positive (ER+) cancers should avoid this supplement.

Back to top

For Healthcare Professionals

Remifemin®, Menofem®, Klimadynon®
Cimicifuga racemosa

Obtained from root of the plant, black cohosh is used as a dietary supplement to relieve the symptoms of menopause and dysmenorrhea.
Black cohosh has antiosteoporotic effects (8) and has been shown to enhance bone formation (9). Black cohosh alone (1)(2)(3) or in combination with other herbs (4), (5) has been shown in clinical studies to be effective in the treatment of menopausal symptoms, but data are conflicting (6)(31)(32)(36)(45). Conclusions of a meta analysis indicate insufficient evidence to support use of black cohosh for menopausal symptoms (40).
Studies evaluating black cohosh to treat hot flashes from breast cancer treatment also yielded mixed results (10)(11)(12). Further supplementation with black cohosh did not enhance bone density, improve menopausal symptoms, or 10-year risk of coronary heart disease in early postmenopausal women (37).

A black cohosh extract was shown to have antidiabetic potential in a study of mice (46). Human studies have yet to be conducted.

In vitro studies show black cohosh decreases prostate cancer cell proliferation (14) and induces an apoptotic response in liver cells (21). However, it also increased the incidence of metastatic disease in mice (16). Whether it has similar effects in breast cancer patients is not well studied, although a retrospective observational study of breast cancer patients found that black cohosh enhanced disease-free survival (15).

Some studies indicate that black cohosh does not possess estrogenic activity. Until this is confirmed, patients with estrogen receptor-positive cancers should use caution when considering the use of black cohosh dietary supplements.
Hepatoxicity has been associated with use of black cohosh (34), but data are conflicting (39).
Patients should consult their physicians before using black cohosh supplements.

  • Dysmenorrhea
  • Menopausal symptoms
  • Premenstrual syndrome
  • Sedation

Black cohosh relieves menopausal symptoms likely by mimicking neurostransmitters: dopaminergic, noradrenergic, serotoninergic and GABAergic effects have been demonstrated (49).
Black cohosh may have estrogenic effects, but data are conflicting (23). Studies also show that it has no effect on LH, FSH, prolactin, or estradiol (24). A black cohosh extract was shown to have antiproliferative and antiestrogenic effects in ER-negative cells. This suggests that black cohosh mediates its effects via an estrogen-independent pathway (25), possibly through HER-2 signaling (26).

Black cohosh also has been investigated for anticancer potential. In an invitro study, it repressed the expression of cyclin D1 and ID3, and inhibited proliferation of HepG2, p53 positive, liver cells (43).
In prostate cancer cells, a black cohosh extract demonstrated antiproliferative effects, via impaired equilibrative nucleoside transporter (ENT) activity, resulting in hindered nucleoside uptake (50).

Hepatotoxicity is a major concern with black cohosh use. Evaluation of liver biopsies from two patients who took black cohosh supplements showed the pattern of pathological injury of liver cells to be identical to toxic necrosis, seen during autoimmune hepatitis (51).

  • Black cohosh should not be confused with blue cohosh.
  • Whether black cohosh possesses estrogenic activity is still not clear. This product should be used under the supervision of a physician.
  • After reviewing 30 independent cases of reported hepatoxicity associated with black cohosh intake, the United States Pharmacopeia’s Botanical Expert Committee decided that black cohosh products should include a statement of caution concerning their use (28).
  • A recent survey reported poor quality control of several black cohosh products (44).
  • Gastrointestinal upset and rashes are most common followed by dizziness, headaches, nausea, and vomiting when higher than normal doses are taken (27)
  • Hepatotoxicity has been reported following use of black cohosh (18)(20)(33)(34)(47).
  • Two cases of liver injury resembling autoimmune hepatitis were reported after taking black cohosh. Both patients responded to treatment with corticosteroids (35).
  • A case of coagulation activation, fluid retention, and transient autoimmune hepatitis has been reported associated with use of black cohosh (38).
  • Bradycardia was observed in a woman following use of black cohosh (41).
  • Orobuccolingual dyskinesia (OBLD), involving interference with speech, tongue-biting, and eating difficulties, has been reported in a 46-year-old woman while taking a herbal supplement containing black cohosh and ginseng (48).

Tamoxifen: Black cohosh may interfere with the action of tamoxifen (42).
Chemotherapy drugs: Black cohosh may increase the toxicity of doxorubicin and docetaxel (13).
Cytochrome P450 3A4: Black cohosh may interact with drugs that are metabolized by CYP3A4 enzyme (17).


  1. Anon. Remifemin: A Plant-based Gynecological Agent. Germany: Schaper & Brümmer; 1997.

  2. Oktem M, Eroglu D, Karahan HB, et al. Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial. Adv Ther. Mar-Apr 2007;24(2):448-461.

  3. Uebelhack R, Blohmer JU, Graubaum HJ, Busch R, Gruenwald J, Wernecke KD. Black cohosh and St. John’s wort for climacteric complaints: a randomized trial. Obstet Gynecol 2006;107(2):247-55.

  4. Chan BY, Lau KS, Jiang B, Kennelly EJ, Kronenberg F, Kung AW. Ethanolic extract of Actaea racemosa (black cohosh) potentiates bone nodule formation in MC3T3-E1 preosteoblast cells. Bone. 2008 Sep;43(3):567-73.

  5. Hernandez Munoz G, Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas. 2003 Mar 14;44 Suppl 1:S59-65.

  6. Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001;19:2739-45.

  7. Rockwell S, Liu Y, Higgins SA. Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. Breast Cancer Res Treat 2005;90(3):233-9.

  8. Zepelin HH, Meden H, Kostev K, et al. Isopropanolic black cohosh extract and recurrence-free survival after breast cancer. Int J Clin Pharmacol Ther. Mar 2007;45(3):143-154.

  9. Davis VL, Jayo MJ, Ho A, et al. Black cohosh increases metastatic mammary cancer in transgenic mice expressing c-erbB2. Cancer Res. 2008 Oct 15;68(20):8377-83.

  10. Tsukamoto S, Aburatani M, Ohta T. Isolation of CYP3A4 Inhibitors from the Black Cohosh (Cimicifuga racemosa). Evid Based Complement Alternat Med. Jun 2005;2(2):223-226.

  11. Cohen SM, O’Connor AM, Hart J, et al. Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause 2004;11(5):575-77.

  12. Levitsky J, Alli TA, Wisecarver J, et al. Fulminant liver failure associated with the use of black cohosh. Dig Dis Sci. Mar 2005;50(3):538-539.

  13. Lontos S, Jones RM, Angus PW, Gow PJ. Acute liver failure associated with the use of herbal preparations containing black cohosh. MJA 2003;179(7): 390-91.

  14. Lude S, Torok M, Dieterle S, et al. Hepatic effects of Cimicifuga racemosa extract in vivo and in vitro. Cell Mol Life Sci. Nov 2007;64(21):2848-2857.

  15. Newall C. Herbal Medicines, A Guide for Health Care Professionals. London: Pharmaceutical Press; 1996.

  16. Zierau O, Bodinet C, Kolba S, et al. Antiestrogenic activities of Cimicifuga racemosa extracts. J Steroid Biochem Mol Biol 2002;80:125-30.

  17. Einbond LS, Wen-Cai Y, He K, et al. Growth inhibitory activity of extracts and compounds from Cimicifuga species on human breast cancer cells. Phytomedicine. Jun 2008;15(6-7):504-511.

  18. Low Dog T, Powell KL, Weisman SM. Critical evaluation of the safety of Cimicifuga racemosa in menopause symptom relief. Menopause. Jul-Aug 2003;10(4):299-313.

  19. Mahady GB, Dog TL, Barrett ML, et al. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause. Mar 12 2008.

  20. Rebbeck TR, Troxel AB, Norman S, et al. A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. Int J Cancer. Apr 1 2007;120(7):1523-1528.

  21. Geller SE, Shulman LP, van Breemen RB, et al. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause 2009 Nov-Dec;16(6):1156-66.

  22. Pierard S, Coche JC, Lanthier P, et al. Severe hepatitis associated with the use of black cohosh: a report of two cases and an advice for caution. Eur J Gastroenterol Hepatol. 2009 Aug;21(8):941-5.

  23. Vannacci A, Lapi F, Gallo E, et al. A case of hepatitis associated with long-term use of Cimicifuga racemosa. Altern Ther Health Med. 2009 May-Jun;15(3):62-3.

  24. Guzman G, Kallwitz ER, Wojewoda C, et al. Liver Injury with Features Mimicking Autoimmune Hepatitis following the Use of Black Cohosh. Case Report Med. 2009;2009:918156.

  25. Shams T, Setia MS, Hemmings R, et al. Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis.  Altern Ther Health Med. 2010 Jan-Feb;16(1):36-44.

  26. Zimmermann R, Witte A, Voll RE, Strobel J, Frieser M. Coagulation activation and fluid retention associated with the use of black cohosh: a case study. Climacteric. 2010 Apr;13(2):187-91.

  27. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev. 2012 Sep 12;9:CD007244.

  28. McKenzie SC, Rahman A.  Bradycardia in a patient taking black cohosh. Med J Aust. 2010 Oct 18;193(8):479-81.

  29. Einbond LS, Soffritti M, Esposti DD, et al. Pharmacological mechanisms of black cohosh in Sprague-Dawley rats. Fitoterapia. 2012 Apr;83(3):461-8.

  30. Teschke R, Schwarzenboeck A, Schmidt-Taenzer W, Wolff A, Hennermann KH. Herb induced liver injury presumably caused by black cohosh: a survey of initially purported cases and herbal quality specifications. Ann Hepatol. 2011 Jul-Sep;10(3):249-59.

  31. Tanmahasamut P, Vichinsartvichai P, Rattanachaiyanont M, Techatraisak K, Dangrat C, Sardod P. Cimicifuga racemosa extract for relieving menopausal symptoms: a randomized controlled trial. Climacteric. 2014 Sep 22:1-7.

  32. Moser C, Vickers SP, Brammer R, Cheetham SC, Drewe J. Antidiabetic effects of the Cimicifuga racemosa extract Ze 450 in vitro and in vivo in ob/ob mice.Phytomedicine. 2014 Sep 25;21(11):1382-9.

  33. Lim TY, Considine A, Quaglia A, Shawcross DL. Subacute liver failure secondary to black cohosh leading to liver transplantation. BMJ Case Rep. 2013 Jul 5;2013.

  34. Sen A.Orobuccolingual dyskinesia after long-term use of black cohosh and ginseng. J Neuropsychiatry Clin Neurosci. 2013 Fall;25(4):E50.

  35. Wuttke W, Jarry H, Haunschild J, Stecher G, Schuh M, Seidlova-Wuttke D.The non-estrogenic alternative for the treatment of climacteric complaints: Black cohosh (Cimicifuga or Actaea racemosa). J Steroid Biochem Mol Biol. 2014 Jan;139:302-10.

  36. Dueregger A, Guggenberger F, Barthelmes J, et al. Attenuation of nucleoside and anti-cancer nucleoside analog drug uptake in prostate cancer cells by Cimicifuga racemosa extract BNO-1055. Phytomedicine. 2013 Nov 15;20(14):1306-14.

  37. Cimicifuga racemosa. Altern Med Rev. 2003 May;8(2):186-9.

Back to top
Back to top
Email your questions and comments to aboutherbs@mskcc.org.

Last Updated